loncastuximab,lenalidomide,polatuzumab vedotin,axicabtagene ciloleucel,lisocabtagene maraleucel,vedolizumab,tafasitamab,selinexor
daiichi sankyo,karyopharm,i-mab,overland adct biopharmaceuticals,gilead,takeda,mitsubishi tanabe,roche,bms,incyte,morphosys
[' vedo', 'dlbcl', 'selinexor', 'lenalidomide', 'axi-cel', 'liso-cel', 'polatuzumab', ' lena', 'loncastuximab tesirine', 'zuma-7', 'tafasitamab', 'imab ']
#ash22 relapse refractory dlbcl.. unanswered question if car t cell therapy improves outcomes of pt who achieve cr with salvage therapy ? 
MD